In a type 1 diabetes rat model [85], SGLT-2 inhibitors were reported to improve blood glucose levels, increase UGE and protect remaining islet β-cell function by reducing the oxidative stress induced by glucose toxicity. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.